股东询价转让计划书 股东深圳科益医药控股有限公司（以下简称"科益医药"或"出让方"）保 证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性 和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次拟参与科兴制药首发前股东询价转让（以下简称"本次询价转让"） 的股东为深圳科益医药控股有限公司； 出让方拟转让股份的总数为 10,062,800 股，占公司总股本的比例为 5.00%； 证券代码：688136 证券简称：科兴制药 公告编号：2025-075 科兴生物制药股份有限公司 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式 进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实施 本次询价转让。截至 2025 年 ...

中国国际金融股份有限公司 关于科兴生物制药股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国国际金融股份有限公司（以下简称"中金公司"）受科兴生物制药股份有限 公司（以下简称"科兴制药"）股东深圳科益医药控股有限公司（以下简称"深圳科 益""出让方"）委托，组织实施本次科兴制药股东向特定机构投资者询价转让（以 下简称"本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创板上 市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上海证券 交易所科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下简称"《询 价转让和配售指引》"）等相关规定，中金公司对参与本次询价出让方的相关资格进 行了核查。 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见如下： 一、本次询价转让的委托 中金公司已收到出让方关于本次询价转让的委托，委托中金公司组织实施本次询 价转让。 二、关于参与本次询价转让股东相关资格的核查情况 （一）核查过程 根据相关法规要求，中金公司已完成出让方相关资格的核查工作，包括核查出让 方提供的营业执照、《承诺及声明函》等， ...

Group 1 - The core point of the article is that Sinovac Biotech (688136.SH) has announced a shareholder inquiry transfer plan, where Shenzhen Koyi Pharmaceutical Holdings Co., Ltd. intends to transfer a total of 10.0628 million shares, representing 5.00% of the company's total share capital [1]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug Bogu Tai® in six countries [1][2] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai® in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai® has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Link Health Biotechnology Group and Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries [1][2] - Bogu Tai is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The target market for this partnership includes over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai in these underserved markets [1] Group 2 - Since its launch in China in March 2024, Bogu Tai has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The collaboration is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2]

Group 1 - The core point of the news is the strategic partnership between Beijing Bokan Gene Technology Co., Ltd. and Sinovac Biotech Ltd. for the exclusive commercialization of the osteoporosis treatment drug Bogu Tai® in six countries, which presents significant market opportunities [1] - Bogu Tai® is a new generation osteoporosis treatment that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures, addressing unmet medical needs in the market [1] - The target market for this partnership includes over 10 million osteoporosis patients with a market size of nearly $1.5 billion, indicating a substantial opportunity for growth [1] Group 2 - Sinovac Biotech is a leading innovative multinational biopharmaceutical company with operations in multiple countries and regions, which has achieved market access and sales in dozens of global markets [2] - The board of Sinovac Biotech views this collaboration as a key milestone in its global expansion strategy, reinforcing its position in the osteoporosis treatment market and providing long-term value for shareholders [2] - Since its launch in China in March 2024, Bogu Tai® has seen significant success, with revenue growth of 248.9% year-on-year in the first half of 2025, indicating strong market demand and performance [1]

Core Viewpoint - 联康生物科技集团 has entered into a strategic cooperation agreement with 科兴制药 for the exclusive commercialization of its innovative osteoporosis treatment drug, 博固泰, in six countries [1] Group 1: Company Overview - 联康生物科技集团's subsidiary, 北京博康健基因科技有限公司, will collaborate with 科兴制药 to expand the market for 博固泰 in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico [1] - 博固泰 is recognized as China's first approved pre-filled teriparatide injection, designed to enhance patient comfort and adherence through a fine needle and precise delivery system [1] Group 2: Product Details - 博固泰 is a next-generation osteoporosis treatment that promotes bone formation and increases bone density, addressing significant unmet medical needs for postmenopausal women at high risk of fractures [1]

Group 1 - The core point of the news is that Link Health Biotechnology Group has signed a strategic cooperation agreement with Sinovac Biotech, granting Sinovac exclusive commercialization rights for the osteoporosis treatment drug, Bogu Tai, in six countries [1] - Bogu Tai is a new generation osteoporosis treatment drug that promotes bone formation and increases bone density, specifically designed for postmenopausal women at high risk of fractures [1] - The cooperation area has over 10 million osteoporosis patients, with a market size of nearly $1.5 billion, providing significant opportunities for Bogu Tai to enter these unmet market needs [1] Group 2 - Since its launch in China in March 2024, Bogu Tai has achieved remarkable success, with revenue growth of 248.9% year-on-year in the first half of 2025 [1] - The partnership is seen as a key milestone in Sinovac's global expansion strategy, reinforcing its position in the osteoporosis treatment market and delivering long-term value to shareholders [2] - The competitive pricing strategy is expected to yield higher profit margins for Bogu Tai, with revenue realization anticipated by the end of 2026 [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 布 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 自願性公佈 科 興 製 藥（ 股 票 代 碼 ： 688136.SH ）是 一 家 領 先 的 創 新 型 跨 國 生 物 製 藥 企 業 ， 其 設 立 並 運 營 6 家 海 外 子 公 司和 辦 事 處 ， 已 通 過 歐盟 、 巴 西 、 菲 律 賓 、 印度 尼 西 亞 等 全球幾十個國家和地區的市場准入並實現銷售。 聯康生物科技集團通過戰略合作拓展博固泰®全球市場 香港，二零二五年九月十二日 — 聯康生物科技集團有限公司（「本公司」），連同其 附屬公司統稱（「本集團」）董事會（「董事會」）欣然宣佈，其全資子公司北京博康健基 因科技有限公司（「北京博康健」）與科興生 ...

Market Overview - The biopharmaceutical sector experienced a slight increase of 0.0% on September 12, with Aopumai leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up by 0.22%, while the Shenzhen Component Index closed at 12996.38, up by 0.13% [1] Top Gainers in Biopharmaceutical Sector - Aopumai (688293) closed at 54.00, with a rise of 4.73% and a trading volume of 20,300 lots, totaling a transaction value of 103 million [1] - Kexing Pharmaceutical (688136) closed at 42.28, increasing by 3.45% with a trading volume of 47,400 lots, amounting to 197 million [1] - Sanofi (688336) closed at 57.07, up by 3.39% with a trading volume of 52,600 lots, totaling 294 million [1] - Tibet Pharmaceutical (600211) closed at 56.60, rising by 3.38% with a trading volume of 93,300 lots, totaling 510 million [1] - Wenqu Pharmaceutical (688488) closed at 16.00, increasing by 2.83% with a trading volume of 86,300 lots, amounting to 134 million [1] Top Decliners in Biopharmaceutical Sector - Rongchang Biopharmaceutical (688331) closed at 107.22, down by 2.68% with a trading volume of 56,400 lots, totaling 611 million [2] - Wanze Shares (000534) closed at 16.02, decreasing by 2.61% with a trading volume of 135,500 lots, amounting to 218 million [2] - Kangtai Biopharmaceutical (300601) closed at 18.63, down by 1.48% with a trading volume of 156,700 lots, totaling 292 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 310 million from institutional investors, while retail investors experienced a net inflow of 132 million [2] - Notable net inflows from retail investors were observed in Kanghua Biological (300841) with 94.86 million, and Xizang Pharmaceutical (600211) with 49.76 million [3] - Conversely, significant net outflows were noted in Rongchang Biopharmaceutical (688331) with 17.13 million and Aopumai (688293) with 18.19 million from retail investors [3]